KYRIX Trademark

Trademark Overview


On Sunday, May 15, 2022, a trademark application was filed for KYRIX with the United States Patent and Trademark Office. The USPTO has given the KYRIX trademark a serial number of 97411368. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, December 17, 2025. This trademark is owned by Bridge Biotherapeutics Inc.. The KYRIX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and biopharmaceutical drug development services; pharmaceutical and biopharmaceutical drug discovery services; pharmaceutical and biopharmaceutical research services

Pharmaceutical and biopharmaceutical preparations, excluding vaccines for human use, for the treatment and prevention of cancer, fibrosis, and inflammatory diseases for therapeutical applications excluding prescription pharmaceutical and medicinal preparations for the treatment and prevention of kidney diseases and disorders, administered in any way other than topically, and excluding anti-inflammatories
kyrix

General Information


Serial Number97411368
Word MarkKYRIX
Filing DateSunday, May 15, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, December 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 31, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biopharmaceutical drug development services; pharmaceutical and biopharmaceutical drug discovery services; pharmaceutical and biopharmaceutical research services
Goods and ServicesPharmaceutical and biopharmaceutical preparations, excluding vaccines for human use, for the treatment and prevention of cancer, fibrosis, and inflammatory diseases for therapeutical applications excluding prescription pharmaceutical and medicinal preparations for the treatment and prevention of kidney diseases and disorders, administered in any way other than topically, and excluding anti-inflammatories

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 4, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, December 4, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBridge Biotherapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNewton,, MA 02458

Party NameBridge Biotherapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNewton,, MA 02458

Trademark Events


Event DateEvent Description
Wednesday, May 18, 2022NEW APPLICATION ENTERED
Wednesday, May 18, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 20, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, May 27, 2022ASSIGNED TO LIE
Wednesday, June 1, 2022PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Friday, March 3, 2023ASSIGNED TO EXAMINER
Wednesday, April 19, 2023NON-FINAL ACTION WRITTEN
Wednesday, April 19, 2023NON-FINAL ACTION E-MAILED
Wednesday, April 19, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 18, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 18, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 18, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 11, 2024FINAL REFUSAL WRITTEN
Wednesday, September 11, 2024FINAL REFUSAL E-MAILED
Wednesday, September 11, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, December 4, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, December 4, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 4, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 5, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 25, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 31, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 31, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, January 23, 2025EXTENSION OF TIME TO OPPOSE RECEIVED
Friday, March 7, 2025TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, April 11, 2025ASSIGNED TO PETITION STAFF
Friday, April 11, 2025POST PUBLICATION AMENDMENT - ENTERED
Sunday, May 11, 2025EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, June 17, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 17, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, December 17, 2025SOU EXTENSION 1 FILED
Wednesday, December 17, 2025SOU EXTENSION 1 GRANTED
Wednesday, December 17, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED